Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Petros Pharmaceuticals Inc (PTPI)
Petros Pharmaceuticals Inc (PTPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,698
  • Shares Outstanding, K 2,201
  • Annual Sales, $ 5,990 K
  • Annual Income, $ -20,040 K
  • 60-Month Beta 1.86
  • Price/Sales 0.51
  • Price/Cash Flow N/A
  • Price/Book 0.48
Trade PTPI with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 111.38%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0510 +63.49%
on 02/05/24
2.2700 -24.30%
on 02/14/24
+0.3333 (+24.06%)
since 01/29/24
3-Month
1.0400 +65.22%
on 01/18/24
2.2700 -24.30%
on 02/14/24
+0.3584 (+26.35%)
since 11/29/23
52-Week
0.9172 +87.34%
on 04/04/23
9.5400 -81.99%
on 04/20/23
-0.3817 (-18.18%)
since 02/28/23

Most Recent Stories

More News
The Urvan Group Issues Letter to AMMO Inc. Shareholders Regarding its Nomination of a Full Slate of Highly Qualified Candidates for Election to the Company’s Board of Directors

Steven Urvan (together with the other participants in his solicitation, the “Urvan Group” or “we”), who owns approximately 17.1% of the outstanding common shares of AMMO, Inc. (NASDAQ: POWW) (“AMMO”...

CLAR : 5.70 (+1.97%)
OLN : 53.51 (+1.59%)
SWBI : 13.59 (+0.82%)
VSTO : 30.93 (+0.42%)
MDA.TO : 14.46 (+2.12%)
SPA : 18.51 (+0.11%)
HD : 380.71 (+0.82%)
POWW : 2.37 (+2.16%)
WRAP : 3.65 (+3.69%)
PTPI : 1.7200 (+2.38%)
AYRO : 1.6800 (-0.59%)
DD : 69.22 (-0.59%)
Petros Pharmaceuticals Responds to Fraudulent Press Release

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today...

PTPI : 1.7200 (+2.38%)
Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky

Dr. Drew to Raise Awareness of Petros Pharmaceuticals’ Mission in The Men’s Health Category and STENDRA® (avanafil)...

PTPI : 1.7200 (+2.38%)
Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics...

PTPI : 1.7200 (+2.38%)
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US

Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local...

PTPI : 1.7200 (+2.38%)
Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces...

PTPI : 1.7200 (+2.38%)
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV

LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's...

CHL.AX : 2.210 (-1.78%)
DCM : 25.60 (-1.35%)
DDDX : 0.0216 (-5.26%)
AAT.VN : 0.020 (-20.00%)
AATGF : 0.0190 (-24.00%)
ASTR.VN : 0.125 (unch)
AMI.VN : 0.135 (unch)
AUUD : 3.88 (+19.02%)
AYRO : 1.6800 (-0.59%)
BNXA.VN : 0.830 (+1.22%)
BNXAF : 0.6069 (+1.10%)
BICX : 1.0000 (+4.17%)
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology

Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device Therapy...

PTPI : 1.7200 (+2.38%)
Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)

Clear Understanding of STENDRA OTC Label to be Key Element in OTC Development Program Company is Pursuing...

PTPI : 1.7200 (+2.38%)
Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights

NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics...

PTPI : 1.7200 (+2.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Petros Pharmaceuticals Inc. is a men's health company. It engages in identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use...

See More

Key Turning Points

3rd Resistance Point 1.9133
2nd Resistance Point 1.8347
1st Resistance Point 1.7573
Last Price 1.7200
1st Support Level 1.6013
2nd Support Level 1.5227
3rd Support Level 1.4453

See More

52-Week High 9.5400
Fibonacci 61.8% 6.2461
Fibonacci 50% 5.2286
Fibonacci 38.2% 4.2111
Last Price 1.7200
52-Week Low 0.9172

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar